FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL. PMID 39531610 · J Clin Oncol · 2025-Feb-10 The record meets most criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result) but the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata. Therefore, the 'phase3_or_definitive' criterion cannot be set to true, making the overall eligibility false. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. PMID 39423355 · J Clin Oncol · 2025-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer. PMID 39378393 · J Clin Oncol · 2025-Feb-10 The study is an oncology randomized trial reporting original results, but it is a Phase II trial (not Phase III/IIIb or definitive Phase II/III), does not involve a drug intervention (only radiation therapy), and does not have a primary or key secondary time-to-event efficacy endpoint (primary endpoint is adverse cosmesis; secondary endpoints include toxicity, not OS/PFS/DFS/EFS/RFS/TTP). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Stereotactic radiosurgery for 1-10 brain metastases to avoid whole-brain radiotherapy: Results of the CYBER-SPACE randomized phase 2 trial. PMID 39340439 · Neuro Oncol · 2025-Feb-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Targeting Amyloid Pathology in Early Alzheimer's: The Promise of Donanemab-Azbt. PMID 39998021 · Pharmacy (Basel) · 2025-Feb-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Hypokalaemia in patients with type 2 diabetes and chronic kidney disease: the effect of finerenone-a FIDELITY analysis. PMID 39380152 · Eur Heart J Cardiovasc Pharmacother · 2025-Feb-08 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Online Radiotherapy: The Paradigm Shift to Real-Time Adaptive Radiotherapy. PMID 39705230 · Dtsch Arztebl Int · 2025-Feb-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A comparative study of mitoxantrone hydrochloride injection and technetium-99 m for tracing axillary sentinel nodes in patients with breast cancer. PMID 39915736 · BMC Cancer · 2025-Feb-06 The record is an ancillary analysis of a Phase III trial evaluating a diagnostic tracer (mitoxantrone hydrochloride) for sentinel lymph node detection in breast cancer. It meets criteria for oncology, human, Phase III, drug intervention, and original result. However, it lacks any time-to-event efficacy endpoint (OS, PFS, DFS, etc.), is not described as randomized, and is a secondary analysis rather than a primary efficacy report. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial. PMID 39915735 · BMC Cancer · 2025-Feb-06 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Updated overall survival in patients with prior checkpoint inhibitor therapy in the phase III TIVO-3 study. PMID 39912344 · Oncologist · 2025-Feb-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China. PMID 39729925 · Vaccine · 2025-Feb-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists. PMID 39592207 · Gut · 2025-Feb-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Atrasentan in Patients with IgA Nephropathy. PMID 39460694 · N Engl J Med · 2025-Feb-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. PMID 39453772 · N Engl J Med · 2025-Feb-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma. PMID 39401002 · Oncologist · 2025-Feb-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study. PMID 39265970 · Oncologist · 2025-Feb-06 The record is an original, prospective, single-arm Phase II trial of a drug (fosnetupitant). It is human and oncology. However, it is excluded because it is non-randomized, not a Phase III/IIIb or Phase II/III trial, and its primary and secondary endpoints are safety measures and complete response rate, not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. PMID 39258838 · N Engl J Med · 2025-Feb-06 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease. PMID 39231444 · Inflamm Bowel Dis · 2025-Feb-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction. PMID 39909533 · BMJ Open · 2025-Feb-05 This is a protocol for a randomized trial investigating the safety of withdrawing heart failure medication in cancer survivors. It lacks results, does not report a Phase III/IIIb or definitive Phase II/III trial, does not include a drug intervention for the cancer, and its primary endpoint is a safety/clinical outcome, not a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial. PMID 39909529 · BMJ Open · 2025-Feb-05 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of intermittent urethral catheter clamping combined with active urination training (ICCAUT) strategy on postoperative urinary dysfunction after radical rectal cancer surgery: single-centre randomised controlled trial (ICCAUT -1) study protocol. PMID 39909516 · BMJ Open · 2025-Feb-05 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal endoscopic microsurgery --A multicenter prospective case-control clinical trial by MONT-R. PMID 39693893 · Eur J Cancer · 2025-Feb-05 The study is a randomized, prospective, multicenter trial with human oncology patients and time-to-event efficacy endpoints (DFS, OS). However, the intervention is a surgical procedure (TEM) versus radical surgery, with no drug-containing intervention. The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and the intervention is non-pharmacologic. Therefore, it fails the drug-intervention requirement and lacks definitive Phase III evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Can metformin prevent cancer relative to sulfonylureas? A target trial emulation accounting for competing risks and poor overlap via double/debiased machine learning estimators. PMID 39030720 · Am J Epidemiol · 2025-Feb-05 The record describes an observational pharmacoepidemiologic study (target trial emulation) comparing metformin to sulfonylureas for cancer incidence in a diabetes cohort. It is not a randomized clinical trial, not a Phase II/III study, and does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) in an oncology therapeutic context. The endpoint is cancer incidence, which is a prevention outcome, not a therapeutic efficacy endpoint in a malignant neoplasm trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group. PMID 38995684 · Clin Infect Dis · 2025-Feb-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study. PMID 39905436 · Arthritis Res Ther · 2025-Feb-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Collagen turnover biomarkers to predict outcome of patients with biliary cancer. PMID 39905306 · BMC Gastroenterol · 2025-Feb-04 While the record is from a randomized oncology study with human participants and time-to-event endpoints, it is ineligible because it does not provide evidence of a Phase III/IIIb or Phase II/III trial, does not specify a drug-containing intervention, and is a biomarker analysis report rather than the formal efficacy report of a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19. PMID 39903535 · JCI Insight · 2025-Feb-04 The trial is a randomized, double-blind, placebo-controlled study of IL-7 in critically ill COVID-19 patients. It is human, includes a drug intervention, and reports original results. However, it is not an oncology study; it focuses on infectious disease (COVID-19). The primary endpoint is lymphocyte recovery, and secondary clinical endpoints are safety, length of stay, infections, and mortality. There is no mention of Kaplan-Meier analysis, hazard ratios, or other time-to-event efficacy endpoints for survival or disease progression. Therefore, it does not meet the oncology or time-to-event criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early Neurologic Deterioration and Efficacy of Dual Antiplatelet in Anterior Versus Posterior Circulation Stroke. PMID 39846303 · J Am Heart Assoc · 2025-Feb-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized phase III study comparing re-irradiation stereotactic body radiotherapy and conventional radiotherapy for painful spinal metastases: Japan Clinical Oncology Group study JCOG2211 (RESCORE study). PMID 39431960 · Jpn J Clin Oncol · 2025-Feb-04 The record is a protocol for a Phase III randomized oncology trial comparing radiotherapy techniques for painful spinal metastases. It meets the criteria for oncology, human, randomized, and phase3_or_definitive. However, it lacks a drug-containing intervention (radiotherapy is a device/modality, not a drug), and the abstract is a protocol without reported results. The primary endpoint (pain response at 12 weeks) could be considered a time-to-event endpoint in principle, but the abstract does not explicitly report time-to-event results (e.g., Kaplan-Meier, HR), and the deterministic_review signals 'time_to_event: false' and 'drug_intervention: false'. Therefore, it is excluded as not meeting the drug intervention requirement and lacking explicit time-to-event result reporting. |
H
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled Trial. PMID 39400063 · J Infect Dis · 2025-Feb-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A randomized phase III study evaluating dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in patients with breast cancer. PMID 39354670 · Jpn J Clin Oncol · 2025-Feb-04 The record is a protocol abstract for a phase III randomized trial with a drug intervention, but it does not report results and the primary endpoint is not a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection. PMID 39172627 · J Infect Dis · 2025-Feb-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 Study Assessing Lot-to-Lot Consistency of Respiratory Syncytial Virus Prefusion Protein F3 Vaccine and Its Immune Response, Safety, and Reactogenicity When Co-administered With Quadrivalent Influenza Vaccine. PMID 38970327 · J Infect Dis · 2025-Feb-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial. PMID 38858818 · Nephrol Dial Transplant · 2025-Feb-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 40009381 · JAMA Netw Open · 2025-Feb-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Algorithm-Based Palliative Care in Patients With Cancer: A Cluster Randomized Clinical Trial. PMID 39982729 · JAMA Netw Open · 2025-Feb-03 Eligible for review as a human malignant-neoplasm randomized trial with original results, but excluded because it does not have a drug-containing intervention (intervention is algorithm-based palliative care process) and lacks a primary or key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. PMID 39960672 · JAMA Netw Open · 2025-Feb-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab. PMID 39901101 · J Headache Pain · 2025-Feb-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pathway Of Low Anterior Resection syndrome (LARS) relief after Surgery (POLARiS): protocol for an international, open-label, multi-arm, phase 3 randomised superiority trial within a cohort, with economic evaluation, process evaluation and qualitative sub-study, to explore the natural history of LARS and compare transanal irrigation and sacral neuromodulation to optimised conservative management for people with major LARS following a high or low anterior resection for colorectal cancer. PMID 39900423 · BMJ Open · 2025-Feb-03 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The effect of deep diaphragmatic breathing on fatigue in patients with metastatic gastrointestinal cancers: a randomized clinical trial. PMID 39899118 · Support Care Cancer · 2025-Feb-03 The study is a randomized oncology trial with human patients, but the intervention is a non-drug behavioral therapy (deep diaphragmatic breathing) and the primary endpoint is fatigue, not a time-to-event efficacy endpoint. Therefore, it does not meet the inclusion criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| 177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial. PMID 39778968 · J Nucl Med · 2025-Feb-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy. PMID 39527097 · Cancer Immunol Res · 2025-Feb-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of a multicentre randomised controlled trial on circulating tumour DNA-guided neoadjuvant treatment strategy for locally advanced rectal cancer (CINTS-R). PMID 39894522 · BMJ Open · 2025-Feb-02 This is a clinical trial protocol for a randomized controlled trial. While it meets criteria for oncology, human, randomized, time-to-event endpoints, and drug intervention, it is not a formal report of trial results. The trial phase is not explicitly stated in the title, abstract, or metadata as Phase III/IIIb or Phase II/III, and the deterministic review flagged phase3_evidence_unclear. Therefore, it is excluded as a protocol-without-results and due to insufficient evidence for the required phase. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis. PMID 39656908 · J Bone Miner Res · 2025-Feb-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses. PMID 39913230 · J Drugs Dermatol · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial. PMID 39892911 · Lancet · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis. PMID 39891702 · Cancer Immunol Immunother · 2025-Feb-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. PMID 39746212 · Obstet Gynecol · 2025-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine. PMID 39746206 · Obstet Gynecol · 2025-Feb-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy. PMID 39699886 · JAMA Ophthalmol · 2025-Feb-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |